Cargando…

Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia

Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator, as add-on treatment to antipsychotics in 161 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Ravi, Turolla, Alessio, Chinellato, Giovanni, Roy, Arjun, Hartman, Richard D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464926/
https://www.ncbi.nlm.nih.gov/pubmed/37349110
http://dx.doi.org/10.1093/ijnp/pyad035
_version_ 1785098570691510272
author Anand, Ravi
Turolla, Alessio
Chinellato, Giovanni
Roy, Arjun
Hartman, Richard D
author_facet Anand, Ravi
Turolla, Alessio
Chinellato, Giovanni
Roy, Arjun
Hartman, Richard D
author_sort Anand, Ravi
collection PubMed
description Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator, as add-on treatment to antipsychotics in 161 treatment-resistant, schizophrenia patients. Ninety-five percent of patients completed 6 weeks (1 discontinued for adverse event), and 89% continued in the extension. Results from the first 100 patients enrolled showed very low attrition over 1 year (77 completers); data pooled from all dose groups showed the Positive and Negative Syndrome Scale total score improved significantly (P < .001; paired t test; last observation carried forward [LOCF]) from baseline at 6 weeks (−9.4), 6 months (−12.7), and 1 year (−14.7); similarly, the proportion of responders (≥20% improvement) increased over time from 6 weeks (16.5%) to 6 months (39%) to 1 year (47.4%). Noteworthy improvement was also observed at each timepoint on the Clinical Global Impression - Severity scale and Clinical Global Impression of Change, indicating progressively increasing efficacy of evenamide up to 1 year.
format Online
Article
Text
id pubmed-10464926
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104649262023-08-30 Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia Anand, Ravi Turolla, Alessio Chinellato, Giovanni Roy, Arjun Hartman, Richard D Int J Neuropsychopharmacol Rapid Communication Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with 46-week extension, indicate very good tolerability with exceptional, clinically important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate modulator, as add-on treatment to antipsychotics in 161 treatment-resistant, schizophrenia patients. Ninety-five percent of patients completed 6 weeks (1 discontinued for adverse event), and 89% continued in the extension. Results from the first 100 patients enrolled showed very low attrition over 1 year (77 completers); data pooled from all dose groups showed the Positive and Negative Syndrome Scale total score improved significantly (P < .001; paired t test; last observation carried forward [LOCF]) from baseline at 6 weeks (−9.4), 6 months (−12.7), and 1 year (−14.7); similarly, the proportion of responders (≥20% improvement) increased over time from 6 weeks (16.5%) to 6 months (39%) to 1 year (47.4%). Noteworthy improvement was also observed at each timepoint on the Clinical Global Impression - Severity scale and Clinical Global Impression of Change, indicating progressively increasing efficacy of evenamide up to 1 year. Oxford University Press 2023-06-22 /pmc/articles/PMC10464926/ /pubmed/37349110 http://dx.doi.org/10.1093/ijnp/pyad035 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Rapid Communication
Anand, Ravi
Turolla, Alessio
Chinellato, Giovanni
Roy, Arjun
Hartman, Richard D
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title_full Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title_fullStr Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title_full_unstemmed Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title_short Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
title_sort phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464926/
https://www.ncbi.nlm.nih.gov/pubmed/37349110
http://dx.doi.org/10.1093/ijnp/pyad035
work_keys_str_mv AT anandravi phase2resultsindicateevenamideaselectivemodulatorofglutamatereleaseisassociatedwithclinicallyimportantlongtermefficacywhenaddedtoanantipsychoticinpatientswithtreatmentresistantschizophrenia
AT turollaalessio phase2resultsindicateevenamideaselectivemodulatorofglutamatereleaseisassociatedwithclinicallyimportantlongtermefficacywhenaddedtoanantipsychoticinpatientswithtreatmentresistantschizophrenia
AT chinellatogiovanni phase2resultsindicateevenamideaselectivemodulatorofglutamatereleaseisassociatedwithclinicallyimportantlongtermefficacywhenaddedtoanantipsychoticinpatientswithtreatmentresistantschizophrenia
AT royarjun phase2resultsindicateevenamideaselectivemodulatorofglutamatereleaseisassociatedwithclinicallyimportantlongtermefficacywhenaddedtoanantipsychoticinpatientswithtreatmentresistantschizophrenia
AT hartmanrichardd phase2resultsindicateevenamideaselectivemodulatorofglutamatereleaseisassociatedwithclinicallyimportantlongtermefficacywhenaddedtoanantipsychoticinpatientswithtreatmentresistantschizophrenia